Stockscreener 앱 받기
14.09
1.74%
-0.25
시간 외 거래:
14.09
전일 마감가:
$14.34
열려 있는:
$14.43
하루 거래량:
136.55K
Relative Volume:
1.79
시가총액:
$363.21M
수익:
-
순이익/손실:
$-31.45M
주가수익비율:
-
EPS:
-
순현금흐름:
$-33.15M
1주 성능:
-18.13%
1개월 성능:
-13.45%
6개월 성능:
-11.16%
1년 성능:
+0.00%
1일 변동 폭
$13.92
$14.81
1주일 범위
$12.33
$17.48
52주 변동 폭
$12.33
$22.00
Contineum Therapeutics Inc Stock (CTNM) Company Profile
명칭
Contineum Therapeutics Inc
전화
(858) 333-5280
주소
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
CTNM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| CTNM | 14.09 | 363.21M | 0 | -31.45M | -33.15M | 0.00 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Contineum Therapeutics Inc 주식(CTNM)의 최신 뉴스
Contineum Therapeutics chief scientific officer sells $101,420 in stock - Investing.com
Contineum Therapeutics chief scientific officer sells $101,420 in stock By Investing.com - Investing.com UK
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain - BioSpace
Contineum Therapeutics Secures FDA Authorization for Novel Pain Treatment PIPE-791 | CTNM Stock News - StockTitan
(CTNM) Trading Signals - Stock Traders Daily
Sectoral Asset Management Inc's Strategic Acquisition in Contine - GuruFocus.com
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve
Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation - Yahoo Finance
Contineum Therapeutics to Attend Upcoming Investor Conferences - BioSpace
Contineum Therapeutics Announces Financial Results for the Quarter Ended September 30, 2024 - Defense World
Contineum Therapeutics' SWOT analysis: promising pipeline drives stock outlook - Investing.com India
Contineum Therapeutics' SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com Canada
Contineum Therapeutics (NASDAQ:CTNM) Releases Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Royal Bank of Canada Lowers Contineum Therapeutics (NASDAQ:CTNM) Price Target to $31.00 - MarketBeat
Ionis to present at upcoming investor conferences - Quantisnow
(CTNM) Trading Report - Stock Traders Daily
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - BioSpace
Contineum (CTNM) Reports Strong Trial Progress, $214M Cash Runway Through 2027 | CTNM Stock News - StockTitan
Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome - Quantisnow
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE - Quantisnow
(CTNM) Proactive Strategies - Stock Traders Daily
Contineum Therapeutics (NASDAQ:CTNM) Stock Rating Upgraded by Baird R W - Defense World
Contineum Therapeutics (NASDAQ:CTNM) Upgraded at Baird R W - MarketBeat
Ionis to hold third quarter 2024 financial results webcast - Quantisnow
Baird bullish on Contineum Therapeutics stock, sees upside from early-stage trials - Investing.com Canada
Contineum stock draws bullish view at Baird (CTNM:NASDAQ) - Seeking Alpha
Contineum Therapeutics (NASDAQ:CTNM) Research Coverage Started at Robert W. Baird - MarketBeat
Baird bullish on Contineum Therapeutics stock, sees upside from early-stage trials By Investing.com - Investing.com South Africa
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis - Quantisnow
EVP Research Swayze Eric converted options into 125 shares and sold $2,031 worth of shares (53 units at $38.31) (SEC Form 4) - Quantisnow
Objective long/short (CTNM) Report - Stock Traders Daily
The US IPO Engine Looks Ready to Speed Ahead in Second Quarter - MSN
Contineum Therapeutics, Inc.'s (NASDAQ:CTNM) largest shareholders are individual investors with 41% ownership, institutions own 28% - Yahoo Finance
Financial Metrics Exploration: Understanding Contineum Therapeutics Inc. (CTNM) Through Ratios - The Dwinnex
Squarepoint Ops LLC Invests $2.64 Million in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - MarketBeat
SEC Form 4 filed by EVP, Chief Human Resourses Ofc Devers Shannon L. - Quantisnow
New insider Devers Shannon L. claimed ownership of 7,909 shares (SEC Form 3) - Quantisnow
Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum - Yahoo Finance
Rhumbline Advisers Makes New Investment in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics (NASDAQ:CTNM) Trading 5% Higher - Defense World
Perceptive Advisors LLC Purchases Shares of 1,566,668 Contineum Therapeutics, Inc. (NASDAQ:CTNM) - MarketBeat
Wall Street SWOT: Contineum Therapeutics stock rides wave of promising assets - Investing.com
Bank of New York Mellon Corp Invests $356,000 in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
(CTNM) Investment Analysis and Advice - Stock Traders Daily
Sandia Investment Management LP Takes $88,000 Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics, Inc.'s Lock-Up Period Will End on October 2nd (NASDAQ:CTNM) - MarketBeat
Contineum Therapeutics, Inc.'s Lock-Up Period To End on October 2nd (NASDAQ:CTNM) - MarketBeat
CD Projekt (OTCMKTS:OTGLY) Shares Up 2.8% - Defense World
Contineum Therapeutics, Inc.’s Lock-Up Period To End on October 2nd (NASDAQ:CTNM) - Defense World
BW LPG (OTCMKTS:BWLLY) Stock Price Down 0.1% - Defense World
Contineum Therapeutics Inc (CTNM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
2.08%
자본화:
|
볼륨(24시간):